Tc 99m P 748

Drug Profile

Tc 99m P 748

Latest Information Update: 08 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer Schering Pharma; Merck & Co
  • Class
  • Mechanism of Action Platelet glycoprotein GPIIb IIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pulmonary embolism

Most Recent Events

  • 08 Sep 2006 Discontinued - Phase-II for Diagnostic imaging in European Union (unspecified route)
  • 08 Sep 2006 Discontinued - Phase-II for Diagnostic imaging in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top